In a landmark decision for patients with chronic sinus conditions, the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) as the first and only medicine specifically indicated for the treatment of allergic fungal rhinosinusitis (AFRS) in adults and children aged six years and older who have a history of sinus surgery. This approval marks a significant milestone for individuals affected by this challenging type of chronic rhinosinusitis, which is often difficult to manage with traditional therapies.
Allergic fungal rhinosinusitis is a persistent inflammatory condition of the sinuses. It is a subtype of chronic rhinosinusitis caused by an extreme allergic reaction to fungi commonly found in warm and humid environments. Patients with AFRS often experience nasal polyps, thick mucus discharge, chronic congestion, and a reduced sense of smell. Severe cases can lead to bone erosion around the sinus cavities and facial deformities. The disease can significantly reduce quality of life and may not respond adequately to standard treatments.
Current management typically includes surgery to remove nasal polyps and long-term systemic corticosteroid therapy. Despite these measures, recurrence is common, creating a persistent cycle of symptoms and medical interventions for patients.
Dupixent is a monoclonal antibody designed to inhibit the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways, two key drivers of type 2 inflammation. Unlike broad immunosuppressants, Dupixent specifically targets these pathways, helping to reduce inflammation without compromising the overall immune system.
This approval adds AFRS to the growing list of Dupixent indications, which now covers nine chronic diseases driven by type 2 inflammation affecting the respiratory system, skin, gastrointestinal tract, and sinuses. These conditions include atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, chronic obstructive pulmonary disease, and bullous pemphigoid.
The FDA approval was based on the Phase 3 LIBERTY-AFRS-AIMS trial, a randomized, double-blind, placebo-controlled study evaluating Dupixent in 62 adults and children with AFRS. Participants received weight- and age-based doses of Dupixent every two or four weeks or placebo over a 52-week period.
Key findings from the trial included:
Primary Endpoint:
Secondary Endpoints:
Safety outcomes were consistent with the known profile of Dupixent. The most common side effects included injection site reactions, eye inflammation, arthralgia, gastritis, insomnia, eosinophilia, and toothache.
Dupixent is administered as a subcutaneous injection and can be given at home or in a clinic after training by a healthcare professional. Adults typically receive 300 mg every two weeks. Pediatric dosing varies based on weight: children weighing 60 kg or more receive 300 mg every two weeks, those between 30 kg and 60 kg receive 200 mg every two weeks, and children between 15 kg and 30 kg receive 300 mg every four weeks. Children aged 12 to 17 should have the injection supervised by an adult, and younger children should receive the injection from a caregiver.
Kenneth Mendez, President and CEO of the Asthma and Allergy Foundation of America, highlighted the significant impact AFRS can have on both children and adults. Chronic congestion, nasal polyps, and thick mucus are not only physically uncomfortable but can also affect mental health, daily functioning, and overall quality of life. Dupixent represents a new hope for patients, offering a therapy specifically approved for the condition.
Alyssa Johnsen, Global Therapeutic Area Head at Sanofi, emphasized that Dupixent reduces multiple symptoms, breaks the cycle of disease recurrence, and lowers the need for repeated surgeries and systemic steroid use. These benefits have the potential to reshape the treatment landscape for AFRS and offer long-term relief for patients.
Dupixent was developed by Regeneron Pharmaceuticals, Inc. and Sanofi using Regeneron’s proprietary VelocImmune® technology, a genetically engineered mouse platform that produces fully human antibodies. By targeting IL-4 and IL-13, Dupixent addresses the underlying inflammatory drivers of type 2 mediated diseases. The development program has included more than 60 clinical trials with over 12,000 participants worldwide, demonstrating its effectiveness across multiple disease areas.
Regeneron and Sanofi continue to explore additional therapeutic applications for Dupixent in type 2 inflammation-driven conditions, including chronic pruritus of unknown origin and lichen simplex chronicus. These trials are ongoing, and efficacy and safety in these new indications have not yet been fully evaluated.
Dupixent has been approved in over 60 countries for various indications, with more than 1.4 million patients receiving the therapy worldwide. In the United States, the DUPIXENT MyWay® program supports patients with access, affordability, and education about the therapy.
Before using Dupixent, patients should inform their healthcare provider about any medical conditions, including eye problems, parasitic infections, upcoming vaccinations, pregnancy, or breastfeeding. Dupixent can cause allergic reactions, eye problems, blood vessel inflammation, psoriasis, and joint pain. Common side effects include injection site reactions, eye inflammation, gastritis, insomnia, eosinophilia, arthralgia, and toothache. Patients are advised to follow all administration instructions and consult healthcare providers if side effects occur.
Dupixent is not intended for rapid relief of breathing problems or acute hives. Patients should not discontinue other medications without consulting their healthcare provider.
The FDA approval of Dupixent for AFRS is a testament to the progress in targeted therapies for type 2 inflammatory diseases. This therapy offers patients relief from chronic symptoms, reduces the need for repeated surgeries, and improves overall quality of life. With ongoing clinical trials and global regulatory submissions, the potential applications of Dupixent continue to expand, bringing hope to more patients living with complex chronic diseases.
Regeneron continues to leverage its VelocImmune and VelociSuite® technologies to discover and develop additional monoclonal antibodies, aiming to address unmet medical needs across multiple therapeutic areas. The collaboration with Sanofi demonstrates the power of combining innovative science with global expertise to deliver transformative medicines.
The approval of Dupixent for allergic fungal rhinosinusitis is a breakthrough for patients who have struggled with chronic sinus inflammation and recurring surgeries. By targeting IL-4 and IL-13 pathways, Dupixent provides a disease-specific treatment option that addresses the underlying inflammatory mechanisms. With proven efficacy, a well-understood safety profile, and a patient-centric support program, Dupixent is poised to redefine the standard of care for AFRS and other type 2 inflammatory diseases.
Patients and caregivers are encouraged to consult their healthcare providers to determine if Dupixent is appropriate for their condition and to discuss proper administration, potential side effects, and monitoring requirements.
Sources:
Disclaimer:
This blog is for informational purposes only and does not constitute medical advice. Dupixent should only be used under the supervision of a qualified healthcare professional. Individuals should consult their healthcare providers for personalized guidance regarding diagnosis, treatment, and potential side effects.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.